Paris, France and Camberley, UK - 23 April 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term COVID-19 research and development (R&D) programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2 continues to mutate around the world. Novacyt also provides an update on its UK operations.

http://novacyt.com/wp-content/uploads/2021/04/Novacyt-RD-Update-ENGLISH-Final-23.04.21.pdf

Attachments

  • Original document
  • Permalink

Disclaimer

Novacyt SA published this content on 23 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 April 2021 13:04:02 UTC.